Specialty Therapy

Asembia’s AXS24 Summit Preview: Our Leaders Look Ahead

As the industry prepares for Asembia’s Specialty Pharmacy Summit, AXS24, our leaders offer valuable insights on themes they expect to see at this year’s event: data-driven solutions, regulatory pressures, specialty pipeline, AI and commercialization.

CoverMyMeds Editorial Team
April 23rd, 2024
Graphic that says "#Asembia24: Looking Ahead"
CoverMyMeds leaders offer valuable insights on themes they expect to see at this year’s event: data-driven solutions, regulatory pressures, specialty pipeline, AI and commercialization.

The excitement is building as we inch closer to Asembia's Specialty Pharmacy Summit, AXS24. This premier event brings together industry thought leaders, executives and decision-makers for a dynamic exchange of insights and discussions about our industry. Gearing up for a productive event, here's what our leaders are most looking forward to at AXS24.

Kevin Kettler, President, CoverMyMeds

“The annual Asembia Summit is an important opportunity to engage with our customers, partners and industry peers. I’m looking forward to discussing the evolving landscape of our industry, particularly the role of data-driven solutions in helping to improve access to essential medications. With solutions that help break down the barriers of complex and fragmented data, CoverMyMeds empowers pharma to make informed decisions that ultimately help improve patient outcomes.”

Collage of the CoverMyMeds leaders featured in article: John Beardsley, Shawn Seamans, Kevin Kettler, Chrissy Hand and Clay Courville

John Beardsley, Senior Vice President, Corporate Strategy & Business Development, CoverMyMeds

“The regulatory landscape, including the imminent implementation of the Inflation Reduction Act (IRA), may present significant challenges for pharmacies and pharma companies, as reflected in the many regulatory and IRA-focused sessions taking place at Asembia this year. Beyond IRA, there are two other factors that could have significant impact on the patient’s experience with therapy: a continued shift of cost to the patient through high-deductible health plans and copay accumulator/maximizer programs, and the demand by patients, providers, employers and government agencies for greater interoperability along the patient journey. It is imperative for pharma companies to evolve their go-to-market approach to consider these changes and their potential impact to patient support and copay assistance programs.”

Clay Courville, Chief Product Officer, CoverMyMeds

“With continued innovation in key therapeutic areas like oncology, the rapid growth of biosimilars and biologics, and dedication to developing specialty medicines for rare and orphan diseases, the industry is poised to make a lasting impact on patient care. Promising therapies targeting MASH (metabolic dysfunction-associated steatohepatitis) and Alzheimer’s Disease, as well as innovation in oncology drugs and the continued growth of GLP-1s for metabolic disorders and beyond, present significant market opportunities. These developments reinforce CoverMyMeds’ commitment to living our mission and developing innovative solutions that help people get the medicine they need to live healthier lives.”

Chrissy Hand, Chief Operating Officer, CoverMyMeds

“The buzz surrounding AI at Asembia this year reflects its growing impact on our industry and how we can best prepare our businesses, programs, care teams and patients for the future. From drug discovery and pipeline optimization, to chatbots and clinician documentation, the rapid adoption of AI across the industry continues to help optimize workflows – freeing up more time so people can focus on the specialized work only humans can do – and redefine the boundaries of what is achievable in healthcare.”

Shawn Seamans, Chief Commercial Officer, CoverMyMeds

“AXS24 provides a platform for cross-industry collaboration and lively in-person discussions around the most pressing industry trends. For instance, in the patient services space, we’re seeing greater system and provider workflow integration in addition to patient services having a more direct impact on brand performance. Systematic interconnectivity is also critical to enable better data flows – and turning that data into the insights pharma needs to fuel next best actions and keep their programs growing is essential. We’re looking forward to the upcoming networking opportunities to stay ahead of a rapidly evolving and dynamic market.”

With a shared enthusiasm for collaboration, our leadership team eagerly anticipates the dynamic discussions that lie ahead.

Connect with us for the latest from AXS24

Did you miss the conference, or were you too busy with meetings while on-site? We’ve got you covered! During the show we provided daily recap blogs that highlighted the top takeaways from key sessions each day. Additionally, our leaders shared their valuable perspectives through a series of brief videos featured on our LinkedIn channel providing further insights on the themes discussed above.

Connect with CoverMyMeds on LinkedIn to join in on the conversation!

To read all of our recaps from this year’s Summit, visit our Asembia 2024 coverage page.

CoverMyMeds Editorial Team

The latest healthcare insights, floated right to your inbox.

There was an error submitting the form. Please refresh or try again later.
iPhone showcasing News and Insights Article